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Purpose: Clinical trials of the PCSK9 inhibitor
alirocumab, an every 2 week injectable monoclonal
antibody, have shown signiﬁcant reductions in LDL-
cholesterol. However, many patients requiring lipid-
lowering therapy are not experienced with self-in-
jected medication. This study assessed patient and
physician perceptions of 2 alirocumab delivery
devices.
Methods: 400 participants (200 physicians, 200
patients) were included from 6 countries. Physicians
(99 primary care physicians [PCPs]; 101 specialists)
had mean practice experience of 17.8 years and an
average of 797 hypercholesterolemic patients. Partic-
ipating patients had LDL-C levels above their goal and
at least one of the following: familial hypercholesterole-
mia, statin intolerance, high cardiovascular risk, and/or
diabetes. Mean patient age was 58.5 years, 51% were
female, and 25.5% had injectable medication experi-
ence. Following device instruction and demonstration,
participants tested either a pre-ﬁlled pen or pre-ﬁlled
syringe, using both 75 and 150 mg doses of single-
blinded placebo into a prosthetic pad. Data were
collected by self-administered questionnaire.
Findings: Participant acceptance of both devices
was positive, with 83-100% agreeing with ease-of-use
statements. After testing, physicians estimated that
66% (pen) and 58% (syringe) of their patients would
be willing to self-inject using the device (relative
increases from pre-testing of 22% and 16%, respec-
tively; both Po 0.05). Specialist estimates were
higher than PCP estimates: for the pen, 60% versus
47% (pre-testing), respectively, and 72% versus 61%
(post-testing); for the syringe, 57% versus 43% (pre-
testing), 63% versus 54% (post-testing; all Po 0.05,September 2015specialist vs PCP). After testing, 72% (pen) and 63%
(syringe) of patient-participants were very willing to
self-inject (relative increases from pre-testing of 26%
[Po 0.05] and 11%, respectively); 96% (pen) and
93% (syringe) were either very willing or somewhat
willing to self-inject. The proportion of patients aged
o60 years who were very willing to self-inject with
either device was numerically (but not statistically)
higher compared with those Z60 years.
Initially, patients with injectable medication experi-
ence were generally more willing to use the pen than
injection-naive patients; after testing there was no
difference between groups. No signiﬁcant differences
were observed in responses to the 2 different doses.
Implications: Responses from physicians and
patients to pre-ﬁlled pen and syringe devices were
positive. Devices were considered easy to operate,
with most patients willing to use and accept self-
injection. Patient willingness to self-inject increased
after demonstration and testing. Results suggest that,
in clinical practice, alirocumab administration by
either pre-ﬁlled pen or syringe would not deter most
physicians from prescribing or most patients from
self-administering. (Clin Ther. 2015;37:1945–1954)
& 2015 The Authors. Published by Elsevier HS
Journals, Inc.
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Clinical TherapeuticsINTRODUCTION
LDL-C is a major risk factor for the development of
atherosclerosis and cardiovascular (CV) disease.1,2
Despite receiving treatment with statins, many pa-
tients at high risk of experiencing CV events do not
achieve optimal LDL-C levels.3–5 Alirocumab is a fully
human monoclonal antibody that binds to and inhib-
its proprotein convertase subtilisin/kexin type 9
(PCSK9), an enzyme that is involved in regulating
circulating levels of LDL-C.6 Clinical trials of
alirocumab, administered as either monotherapy or
with background statin therapy (with and without
other lipid-lowering therapies), have shown the ther-
apeutic potential to reduce LDL-C levels, with signiﬁ-
cant reductions from baseline after 24 weeks of
treatment ranging from 47% to 61%.7–10
Alirocumab is administered via subcutaneous injec-
tion. Two delivery devices have been used in alirocu-
mab Phase III clinical trials, a preﬁlled syringe9 and a
preﬁlled pen (also termed “autoinjector”), using a
1-mL injection volume for doses of 75 or 150 mg.7,8,10
However, many patients requiring lipid-lowering
therapy will not have experience with injectable
medications and, similarly, physicians will have little
experience prescribing injectable lipid-lowering drugs.
The only such agent currently available commercially
is mipomersen, an antisense oligonucleotide targetingParticipants
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1946apolipoprotein B. Mipomersen is licensed in the United
States only for the treatment of homozygous familial
hypercholesterolemia (FH), which affects an estimated
1 in 1 million individuals in most parts of the world.11
It is therefore important to understand how patients
and physicians perceive alirocumab administration
devices. The present study was designed to assess
patient and physician perceptions of the ease of use
and acceptance of those devices.
PATIENTS AND METHODS
Participants
A total of 400 participants (200 physicians and 200
patients) were included from 6 countries: 100 physicians
and 100 patients from the United States, and 20 of each
from 5 European countries (France, the United Kingdom,
Spain, Germany, and Italy) (Figure 1). Of the physicians,
99 were primary care physicians (PCPs), and 101 were
specialists (cardiologists, endocrinologists, diabetologists,
lipidologists, nephrologists [Germany only], and
chemical pathologists [United Kingdom only]) (Table I).
Patients enrolled were not at their LDL-C goal (as set by
their physician) and had at least 1 of the following: FH,
statin intolerance, high CV risk, and/or diabetes.
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Table I. Physician and patient participants according to category and country. Values are given as
number (%).
Study Group
United
States France
United
Kingdom Germany Spain Italy Overall
Physicians
PCPs 49 (49.0) 10 (50.0) 10 (50.0) 10 (50.0) 10 (50.0) 10 (50.0) 99 (49.5)
Specialists 51 (51.0) 10 (50.0) 10 (50.0) 10 (50.0) 10 (50.0) 10 (50.0) 101 (50.5)
Endocrinologists/
diabetologists
22 6 4 2 5 3 42
Cardiologists 25 2 4 4 5 5 45
Lipidologists 4 2 1 2 0 2 11
Nephrologists 0 0 0 2 0 0 2
Chemical pathologists 0 0 1 0 0 0 1
Total 100 (50.0) 20 (10.0) 20 (10.0) 20 (10.0) 20 (10.0) 20 (10.0) 200
Patients*
High CV risk 55 (55.0) 10 (50.0) 9 (45.0) 11 (55.0) 9 (45.0) 10 (50.0) 104 (52.0)
Diabetic 28 (28.0) 6 (30.0) 8 (40.0) 7 (35.0) 8 (40.0) 6 (30.0) 63 (31.5)
Statin intolerant 16 (16.0) 3 (15.0) 3 (15.0) 2 (10.0) 3 (15.0) 3 (15.0) 30 (15.0)
FH 1 (1.0) 1 (5.0) 0 0 0 1 (5.0) 3 (1.5)
Total 100 (50.0) 20 (10.0) 20 (10.0) 20 (10.0) 20 (10.0) 20 (10.0) 200
PCP ¼ primary care physician; CV ¼ cardiovascular; FH ¼ familial hypercholesterolemia.
*Patient categories were deﬁned as follows. All patient participants were diagnosed as having a high LDL-C level that was not
at goal, in addition to 1 of the following factors.
High CV risk: diagnosed with, or experienced, at least 1 CV risk factor (from: unstable angina; heart attack/myocardial
infarction; stroke/transient ischemic attack; peripheral arterial disease; bypass surgery; percutaneous coronary intervention
[angioplasty] with or without stent; chronic heart disease, or chronic kidney disease) OR diagnosed with diabetes and with
at least 2 additional CV risk factors (from: hypertension/high blood pressure; retinopathy, neuropathy; microalbubinuria
[urine albumin]; family history of chronic heart disease); not diagnosed with FH or statin intolerant.
Diabetic: diagnosed with diabetes and o2 additional CV risk factors; not diagnosed with FH or statin intolerant.
Statin intolerant: discontinued Z2 statins due to muscle-related adverse effects; not currently receiving high-dose statins; not
diagnosed with FH. Patients receiving low-dose statins could still be considered as statin-intolerant if they had discontinued higher
dose statins previously. “High-dose statins” were deﬁned as simvastatin 40 to 80 mg, pravastatin 40 to 80 mg, rosuvastatin 20 to
40 mg, lovastatin 60 mg, ﬂuvastatin 80 mg, or pitavastatin 4 mg. All lower doses were considered as “low-dose statins.”
FH: diagnosed with FH and has a family history of cardiac death before 50 years of age; diagnosed with high cholesterol at age
r50 years; questions on family history and high cholesterol were posed to validate the patient-reported diagnosis of FH.
E.M. Roth et al.Research Association, British Healthcare Business
Intelligence Association). Prior consent was sought
with participants before starting the research. This
consent included permission for audio and video
recording (and storage) and agreement to be watched
live with study sponsors in attendance.
Data Collection
Data were collected via self-administered question-
naires in a structured interview. ParticipantSeptember 2015assignment and study ﬂow are shown in Figure 1.
The interview was conducted in a central location in
each country and involved a 30-minute self-comple-
tion exercise. A moderator was present for assistance,
although the interview was designed to ensure the
moderator had no involvement in data collection. The
identity of alirocumab was blinded, with an un-
branded name (“Voypaz”) used instead.
After introduction to the drug, participants (physi-
cians or patients) were asked about willingness to1947
Clinical Therapeuticsprescribe or self-inject before using the device (intro-
ductory drug details and speciﬁc questions are shown
in the Supplemental Materials [see the online version
at http://dx.doi.org/10.1016/j.clinthera.2015.07.008]).
Participants were randomly assigned to interact with
either the pen or the syringe. After device training
(which involved instruction and demonstration with a
prosthetic pad), participants tested each of 2 doses (75
and 150 mg) by pad injection. The actual substance
injected was a placebo developed to mimic the viscosity
of alirocumab. Both devices used a 27-G thin-walled
needle, although this detail was not shared with
participants. After testing, participants completed a
questionnaire for each dose consisting of a list of
statements about device operation and ease of use.
Participants indicated whether they agreed or disagreed
with each statement. Statements were presented in a
random order; some statements were speciﬁc to patients
(and not shown to physicians) and some were speciﬁc to
the pen (and were not shown to participants using the
syringe).
After testing the devices and responding to the ease-
of-use statements, participants were asked again about
their willingness to prescribe or self-inject (speciﬁc
questions are shown in the Supplemental Materials
[available in the online version at http://dx.doi.org/10.
1016/j.clinthera.2015.07.008]). Physicians were asked
to estimate the percentage of their patients (with
uncontrolled LDL-C) who would be willing to self-
inject. Patients indicated their level of willingness to
self-inject from 5 options (very willing, somewhat
willing, neither willing nor unwilling, somewhat un-
willing, and very unwilling).
An “Instructions for Use” document (including
storage, preparation, and injection instructions for the
device) was provided to participants, based on the
intended actual alirocumab device packaging. Moder-
ators demonstrated how to use the device and read from
a script to describe the process (the script was based on
the “Instructions for Use” product insert) to ensure
consistency. The pen and syringe devices had equal
exposure across patients and physicians. The order in
which doses were seen was rotated to avoid bias (ie, 75
and 150 mg were seen ﬁrst an equal number of times).
The prosthetic pad was a multilayered soft tissue
pad used to train and allow patients to practice
subcutaneous injection techniques. The pad was ﬂex-
ible with multiple tissue layers representing the epi-
dermis, dermis, fat, and muscle layers allowing1948patients to pinch the “skin” and inject. The pad was
equipped with a strap which allowed the moderator to
demonstrate the injection on his or her thigh; respond-
ents were allowed to inject on their thigh or stomach
or on the table top. No physician or patient received
an actual injection. Injection training via prosthetic
pad has previously been shown to increase patient
conﬁdence in self-administering injections.12
Statistical Analysis
The sample was constructed so that signiﬁcance
testing could be conducted at each level of design. To
have an adequate number for signiﬁcance testing, the
cell size could not fall below 20. The sample size was
determined to be n ¼ 400 (with 200 physicians/
patients [200 testing the pen/syringe, and 200 testing
the 75-/150-mg doses]). Furthermore, in addition to
the physician/patient, pen/syringe, and 75-/150-mg
dose categories, there was a geography category, with
200 respondents in the United States and 200 in the
European Union. Of the 200 respondents in the
European Union, there were 40 in each of the 5
countries (20 evaluating the pen, and 20 evaluating
the syringe).
P values were calculated by using SPSS software,
version 21 (IBM SPSS Statistics, IBM Corporation,
Armonk, New York). A signiﬁcance level of 0.05 and
the Bonferroni correction were used for all tests.
Pairwise comparisons of proportions were performed
by using a z test when the test variable was catego-
rical, and pairwise comparisons of means were per-
formed by using a t test when the variable was scale.
Because no signiﬁcant differences were found between
the 2 doses tested, results for the 2 doses were pooled.
RESULTS
Baseline Characteristics of Participants
Physicians had mean practice experience of 17.8
years since residency and were managing an average
of 797 patients with hypercholesterolemia, with 77%
of them receiving lipid-lowering therapy. None of the
physicians had previously been involved in alirocu-
mab trials.
The mean age of patients was 58.5 years; 51%
were female, and 25.5% had previous injectable
medication experience (any medication). Eighty-four
percent were white, 12.5% were black/African
American, 2% were Latin American/Hispanic, and
the remaining 1.5% were either Asian/Paciﬁc Islander,Volume 37 Number 9
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Figure 2. (A) Physician estimates of patient
willingness to self-inject (pre-testing
and post-testing) and primary care
physicians (PCPs) versus specialists
for (B) the pen and (C) syringe.
*P o 0.05, after testing versus
before testing. In panel A, estimates
were higher after testing with the
pen (66%) than with the syringe
(58%; P o 0.05); estimates with
the pen and syringe were not sig-
nificantly different for the other
comparisons.
E.M. Roth et al.Native American/Indian or Other (0.5% each). The
majority of patients (88%) were receiving a statin.
Patient LDL-C levels and details of previous injectable
medications were not recorded. Characteristics of the
patients assigned to the preﬁlled pen or syringe group
were similar (eg, mean age 58 years [pen] and 59 years
[syringe]; 52% [pen] and 50% [syringe] were female;
and 25% [pen] and 26% [syringe] had previous
injectable medication experience) (Supplemental
Table I [available in the online version at http://dx.
doi.org/10.1016/j.clinthera.2015.07.008]). Characteris-
tics of patients in the United States and European
Union were also similar (Supplemental Table II
[available in the online version at http://dx.doi.org/10.
1016/j.clinthera.2015.07.008]).
Results for Physicians
Physician acceptance of both devices was positive, with
83% to 100% agreeing with statements regarding device
operation and ease of use (see Supplemental Figure 1 in
the online version at http://dx.doi.org/10.1016/j.clinthera.
2015.07.008). Example statements included “The
injection is easy for patients to learn,” and “I would
recommend the Voypaz pen to my patients.”
After instruction and testing of devices, physicians
considered that 66% (pen) and 58% (syringe) of their
patients would be willing to use self-injectable alir-
ocumab (relative increases from before testing of 22%
and 16%, respectively; both P o 0.05) (Figure 2A).
Physician estimates after testing were higher with the
pen (66%) than with the syringe (58%; P o 0.05).
Specialist estimates were higher than PCP estimates:
for the pen, estimates were 60% versus 47% (before
testing), respectively, and 72% versus 61% (after
testing); for the syringe, estimates were 57% versus
43% (before testing) and 63% versus 54% (after
testing) (all, P o 0.05 specialist vs PCP) (Figures 2B
and C). There were no signiﬁcant differences between
responses of physicians based in the United States
versus the European Union (Table II).
Results for Patients
Patient acceptance of both devices was also pos-
itive, with 86% to 100% agreeing with statements
regarding device operation and ease of use (see
Supplemental Figure 2 in the online version at http://
dx.doi.org/10.1016/j.clinthera.2015.07.008). Example
statements included “The pen is convenient to use,
which can make it easy for you to stay with yourSeptember 2015 1949
Table II. Physician responses according to region (United States or European Union): percentage of patients
whom physicians estimate would be willing to self-inject.
Device Region
Before Testing
Device, %
After Testing
Device, %
Relative
Change, %
Pen United States 52 65 26*
European Union 56 68 22
Syringe United States 50 58 17
European Union 50 59 17
*P o 0.05, before testing versus after testing.
Clinical Therapeuticstreatment,” and “Visual and audio cues conﬁrm when
the injection begins and the injection is completed.”
After instruction and testing, 72% (pen) and 63%
(syringe) of participating patients indicated that they
were very willing to self-inject the drug if their
physician recommended it to them (relative increases
from before testing of 26% [P o 0.05] and 11%,
respectively) (Figure 3A). More patients were very
willing to self-inject after testing with the pen (72%)
than with the syringe (63%; P o 0.05).
Most patients stated they were at least somewhat
willing to self-inject with both devices (Table III).
After testing, 96% (pen) and 93% (syringe) of patients
indicated that they were either “very willing” or
“somewhat willing” to self-inject (relative increases
from before testing of 6.7% and 4.5%, respectively;
both nonsigniﬁcant). The majority of patients indi-
cated that they would be conﬁdent in self-injecting on
their own at home (74% with the pen, 66% with the
syringe; patients were only asked about injecting at
home after they had tested the devices).
The proportion of patients agedo60 years who were
very willing to self-inject with either the pen or syringe
was numerically but not statistically different from
corresponding ﬁgures for patients aged Z60 years
(Figure 3B). Initially, patients with injectable medi-
cation experience were generally more willing to use
the pen than injection-naive patients; after instruction
and testing, there was no difference between groups
(Figure 3C). Among female subjects who tested the pen,
52% indicated before testing that they were very willing
to self-inject; this value increased to 69% after testing
(P o 0.05). There were numerical but not statistically
signiﬁcant differences in corresponding ﬁgures for male
subjects who tested the pen or either sex who tested the1950syringe (Table IV). Willingness to self-inject increased for
both devices across all patient CV risk categories, except
for FH (100% were “very willing” both pre-testing and
post-testing) (Table V). No signiﬁcant differences were
observed in participant responses to the 2 different doses.
The majority of patients in both the United States
and the European Union were very willing to self-
inject after testing the devices, although a greater
proportion of US patients (82%) stated that they
would be very willing to self-inject with the pen after
testing compared with those from the European Union
(62%; P o 0.05) (Table VI). The majority of patients
from the European Union stated they were at least
somewhat willing to self-inject with the pen. However,
there were no regional differences for the syringe.
DISCUSSION
The main ﬁndings of this research were that physician
and patient acceptance of alirocumab injection devices
was positive. Although nearly 75% of patients had no
previous experience with injectable medication, the
devices were considered easy to use, with most patients
willing to use and accept self-injection after instruction
and testing. Both devices scored well for usability,
although willingness to self-inject or prescribe was
higher with the pen than with the syringe. Importantly,
patients were more willing to self-inject after demon-
stration and testing of the devices (as were physician
estimates of the percentage of patients who would be
willing to self-inject). This ﬁnding indicates that training
would be important to increase patient acceptance of the
alirocumab administration devices.
Among the physician participants, willingness to
prescribe a lipid-lowering medication using either of
the devices was higher among specialists comparedVolume 37 Number 9
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Figure 3. Patients reporting they would be “very will-
ing” to self-inject pre-testing and post-test-
ing, according to: (A) device; (B) for those
aged Z60 years versus those aged o60
years; and (C) according to level of injection
experience. *P o 0.05, after testing versus
before testing. In panel A, more patients
were very willing to use the devices after
testing with the pen (72%) than with the
syringe (63%; P o 0.05); results with the
pen and syringe were not significantly differ-
ent for the other comparisons.
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September 2015with PCPs. Among patient participants, there were
numerical (although not statistically signiﬁcant) differ-
ences in the proportion of patients who were “very
willing” to self-inject, suggesting that the devices were
more acceptable to patients agedo60 years compared
with those aged Z60 years. There were no signiﬁcant
differences between physician estimates of patient
willingness and patient-reported willingness to self-
inject. Acceptance of both devices was positive across
patient CV risk categories (eg, high CV risk, statin
intolerance, diabetes, FH). Of the patients with FH,
100% gave “very willing” responses (although the
group included only 3 patients). It could be speculated
that this group of patients (who have genetically
elevated LDL-C levels and are at lifelong increased
risk for CV disease) are more willing to accept lipid-
lowering medication by injection. This study included
participants from the United States and 5 countries
from the European Union. Responses from physicians
based in the United States and from the European
Union were highly similar. A larger proportion of
patients from the United States compared with those
from the European Union stated after testing that they
would be very willing to use the pen; however, there
was no difference for the syringe.
Results from the present study indicate that the
majority of patients would be willing to use either of
the alirocumab injection devices. However, it is important
to understand patient acceptance of actual injections of
alirocumab given to them in practice. A limitation of this
study was that patients did not perform injections on
themselves and did not use the active drug. A question-
naire assessing patient acceptance of actual self-
administered alirocumab injections has been developed
based on interviews with patients involved in the Phase III
clinical trials of alirocumab. Preliminary results suggest
high patient acceptance of alirocumab injections, with
patients ﬁnding both the preﬁlled pen and syringe easy to
use.13 In addition, a device questionnaire was given to
patients enrolled in the ODYSSEY CHOICE II trial
(ClinicalTrials.gov: NCT02023879). Data from
completed trials also indicate high patient acceptance of
alirocumab injections. Adherence to injections (the per-
centage of days that patients received injections according
to the dosing schedule) was reported for 2 studies: 98%
used the preﬁlled syringe in ODYSSEY LONG TERM
(over 78 weeks’ duration),9 and 98% used the preﬁlled
pen in ODYSSEY COMBO I (52 weeks).8 Furthermore,
in the ODYSSEY CHOICE II Phase III study1951
Table III. Patient willingness to self-inject for overall participant population.
Study Group
Very
Willing, %
Somewhat
Willing, %
Neither Willing
Nor Unwilling, %
Somewhat
Unwilling, %
Very
Unwilling, %
Pen (n ¼ 100)
Before testing 57 33 8 2 0
After testing 72 24 2 2 0
Syringe (n ¼ 100)
Before testing 57 32 5 4 2
After testing 63 30 1 3 3
Table IV. Male and female patients reporting they would be “very willing” to self-inject pre-testing and
post-testing, according to device.
Study Group Before Testing Device, % After Testing Device, % Relative Change, %
Male patients
Pen (n ¼ 48) 63 75 19
Syringe (n ¼ 50) 60 66 10
Female patients
Pen (n ¼ 52) 52 69 33*
Syringe (n ¼ 50) 54 60 11
*P o 0.05, before testing versus after testing.
Table V. Percentage of patients who were “very willing” to self-inject by using alirocumab devices according to
cardiovascular (CV) risk category.
Study Group Before Testing Device, % After Testing Device, % Relative Change, %
High CV risk
Pen (n ¼ 46) 48 59 23
Syringe (n ¼ 58) 62 66 6
Diabetes
Pen (n ¼ 31) 65 87 34
Syringe (n ¼ 32) 53 59 11
Statin intolerance
Pen (n ¼ 21) 62 76 23
Syringe (n ¼ 9) 33 56 70
FH
Pen (n ¼ 2) 100 100 0
Syringe (n ¼ 1) 100 100 0
FH ¼ familial hypercholesterolemia.
Clinical Therapeutics
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Table VI. Patient willingness to self-inject according to region.
Group
Very
Willing, %
Somewhat
Willing, %
Neither Willing
Nor Unwilling, %
Somewhat
Unwilling, %
Very
Unwilling, %
EU patients
Pen (n ¼ 50)
Before testing 52 38 6 4 0
After testing 62 34 2 2 0
Syringe (n ¼ 50)
Before testing 56 30 8 2 4
After testing 60 34 2 2 2
US patients
Pen (n ¼ 50)
Before testing 62 28 10 0 0
After testing 82* 14* 2 2 0
Syringe (n ¼ 50)
Before testing 58 34 2 6 0
After testing 66 26 0 4 4
*P o 0.05 versus European Union (EU).
E.M. Roth et al.(ClinicalTrials.gov identiﬁer: NCT02023879; manuscript
in preparation), the overall experience in performing self-
injection at home was rated as 6 or 7 (7 ¼ extremely
satisﬁed) by 93% of patients. In all the Phase III trials,
patients could choose to self-inject at home or have a
caregiver administer the drug. In the ODYSSEY MONO
trial, 92% of patients who were allocated to receive
alirocumab opted to self-inject at home (data not reported
for other completed trials).10 The patient groups recruited
in this study are represented in the ODYSSEY Phase III
clinical trial program (heterozygous FH14,15 and statin
intolerance16). Patients with diabetes were not speciﬁcally
recruited although they were well represented in the
ODYSSEY Phase III clinical trial program.CONCLUSIONS
Acceptance of the alirocumab preﬁlled pen and sy-
ringe devices was positive. The devices were consid-
ered easy to operate, with most patients willing to use
and accept self-injection, particularly after training.
Results suggest that, in clinical practice, the preﬁlled
pen or syringe devices would not deter most physi-
cians from prescribing and would not deter most
patients from self-administering the drug.September 2015ACKNOWLEDGMENTS
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E.M. Roth et al.INTRODUCTION TO ALIROCUMAB
(BLINDED AS ‘VOYPAZ’)
Today you will be looking at an injection device for a
potential new medication for high cholesterol, which will
be referred to as Voypaz. Voypaz is an approved,
unbranded name which you will see in this research only.
This is a working name for product testing purposes; this
is not the real product name. You will be given an
opportunity to look at the device, use the device, and then
review statements which relate to the device.
You will be looking at two doses of the device today.
Before you look at the device, here is a brief summary
about the product with which the device will be used.
Note that the product itself is not the focus of our
discussion, but we’ll go through the information to help
you better understand the statements you will see.*C
SVoypaz is a new prescription medication currently
under development for patients who need addi-
tional help lowering their high cholesterol. In clinical trials, Voypaz has been shown to lower
‘bad’ cholesterol (LDL) by an additional 45–61%
on top of your current statin therapy, and by
45–47% when statins cannot be taken due to side
effects. There have been no serious safety issues observed
for Voypaz and signiﬁcantly fewer muscle pain or
liver side effects.* The most frequent side effects
seen in clinical trials have been minor injection-site
reactions such as redness or irritation. Voypaz can
be used safely with statins and other commonly
used medications for high blood pressure, stroke
prevention, kidney disease, and diabetes Voypaz is a medication that you self-inject into your
skin with a ready-to-use, single-use, disposable injec-
tion device once every 2 weeks. The injection can be
given by a family caregiver or friend if desired There are two doses available for Voypaz, 75 mg and
150 mg, and your doctor will determine which one is
right for you. Regardless of dose, both are delivered
with the same amount of liquid (1 mL) with the same
device. Voypaz is kept in a refrigerator at a cold temper-
ature and brought to room temperature before
using (which takes about 30–40 minutes)If you have any questions or uncertainties about the
product information, check with the moderator before
continuing.ompared with statins
eptember 2015QUESTIONS ASKED TO PHYSICIANS BEFORE
AND AFTER TESTING THE DEVICES
Before Testing
Thinking of only the patients with uncontrolled
LDL-C and a high CV risk proﬁle whom you would
consider prescribing Voypaz to, what percentage do
you think would be willing to self-inject Voypaz?
(i.e. 100% is all of the patients who are suitable and
you consider prescribing Voypaz to)
After Testing
Now that you have had a chance to read the
instructions and try the device…
Thinking of only the patients with uncontrolled
LDL-C and a high CV risk proﬁle whom you would
consider prescribing Voypaz to, what percentage do
you think would be willing to self-inject Voypaz? (i.e.
100% is all of the patients who are suitable and you
consider prescribing Voypaz to)
______% (ﬁll in from 0% to 100%)QUESTIONS ASKED TO PATIENTS BEFORE
AND AFTER TESTING THE DEVICES
Before Testing
After reading this information about Voypaz, how
willing would you be to self-inject Voypaz if it was
recommended to you by your doctor?
Select answer which best applies□ I would be very willing to self-inject Voypaz if my
doctor recommended it to me□ I would be somewhat willing to self-inject Voypaz
if my doctor recommended it to me□ I would be neither willing nor unwilling to self-
inject Voypaz if my doctor recommended it to
me□ I would be somewhat unwilling to self-inject
Voypaz if my doctor recommended it to me□ I would be very unwilling to self-inject Voypaz if
my doctor recommended it to meAfter Testing
Now that you have had a chance to read the
instructions and try the device, how willing would
you be to self-inject with Voypaz to treat your high
cholesterol, if your doctor recommended this medi-
cation to you?1954.e1
Clinical TherapeuticsSelect answer which best applies□1I would be very willing to self-inject Voypaz if my
doctor recommended it to me□ I would be somewhat willing to self-inject Voypaz
if my doctor recommended it to me954.e2□ I would be neither willing nor unwilling to self-
inject Voypaz if my doctor recommended it to me□ I would be somewhat unwilling to self-inject
Voypaz if my doctor recommended it to me□ I would be very unwilling to self-inject Voypaz if
my doctor recommended it to meVolume 37 Number 9
Intuitive design, with user-friendly color-coding and clear labeling, helps make
the pen easy to explain
The injection is easy for patients to learn
The pen is easy to use
Each dosage option is distinguishable by color to help ensure the proper dose
is being used
There is a small amount of the dose volume in each injection (1 mL)
The window turns yellow when the injection is completed so patients know that 
the full dose has been delivered
An audible click sound confirms for patients that the injection has started
Visual and audio cues confirm when the injecion begins and when the injection
is completed
One injection every 2 weeks is convenient for patients, especially those taking
multiple medications
Patients can activate the injection with the click of a button
The pen is convenient to use, which can help patients adhere to their treatment
The design of the pen, combined with clear directions, can help make it easy
for patients to understand how to inject properly with this device
I would recommend the Voypaz pen to my patients
The pen uses a thin, hidden needle that retracts automatically out of patients’
view
The pen uses a thin needle that remains hidden throughout the entire injection,
which may help allay my patients’ fears
The pen requires minimal force to activate
The activation button is easy to push
The prefilled syringe is easy to use
Each dosage option is distinguishable by color to help ensure the proper dose
is being used
Intuitive design, with user-friendly color-coding and clear labeling, helps make
the syringe easy to explain
The injection is easy for patients to learn
There is a small amount of the dose volume in each injection (1mL)
One injection every 2 weeks is convenient for patients, especially those taking
multiple medications
The design of the prefilled syringe, combined with clear direction, can help
make it easy for patients to understand how to inject properly with this device
I would recommend the Voypaz prefilled syringe to my patients
98%
91%
90%
99%
98%
96%
96%
95%
93%
93%
96%
100%
97%
90%
90%
98%
98%
97%
95%
83%
96%
93%
99%
96%
96%
A
B
Supplemental Figure 1. Responses to statements regarding device operation and ease of use from physicians
for (A) the prefilled pen and (B) the prefilled syringe (% agreement).
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The pen is easy to use
Self-injection is easy to learn
Learning to use the pen is easy because all of the parts are clearly labeled and
color-coded
The directions are clear, which helps to make learning to use the prefilled pen
easy
The color-coding on each dosage option helps ensure that you are using the 
proper dose
There is a small amount of the dose volume in each injection (1 mL)
A simple self-injection allows you to take your medication at home
The window turns yellow when the injection is completed so that you know
when the injection is finished
When you hear the first click sound, you know the injection has started
Visual and audio cues confirm when the injection begins and when the injection
is completed
One injection every 2 weeks is convenient
You can simply activate the injection with the click of a button
The design of the pen, combined with clear directions, can help make it easy to
learn to inject properly
The design combined with clear directions can help make it easy to get started
on your treatment
Staying on therapy is simple with an easy-to-use pen
The pen is convenient to use, which can make it easy for you to stay with your
treatment
I would be willing to use the Voypaz pen
The pen uses a thin needle that remains hidden throughout the entire injection
When you self-inject with the pen, a thin, hidden needle automatically retracts
so you don’t see it
The activation button is easy to push
The pen requires a light push of the button to activate
The directions are clear, which helps to make learning to use the prefilled
syringe easy
The prefilled syringe is easy to use
Learning to use the prefilled syringe is easy because all of the parts are 
clearly labeled and color-coded
Self- injection is easy to learn
The color-coding on each dosage option helps ensure that you are using the 
proper dose
There is a small amount of the dose volume in each injection (1mL)
A simple self-injection allows you to take your medication at home
One injection every 2 weeks is convenient
The design combined with clear directions can help make it easy to get started
on your treatment
The design of the prefilled syringe, combined with clear directions, can help
make it easy to learn to inject properly
Staying on therapy is simple with an easy-to-use prefilled syringe
I would be willing to use the Voypaz prefilled syringe
100%
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Supplemental Figure 2. Responses to statements regarding device operation and ease of use from patients for
(A) the prefilled pen and (B) the prefilled syringe (% agreement).
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Supplemental Table I. Characteristics of patients according to randomization groups (pen or syringe).
Characteristic Pen (n ¼ 100) Syringe (n ¼ 100)
Mean age, y 58.0 59.0
Sex, %
Male 48 50
Female 52 50
Injection experience, %
Injection experienced 25 26
Injection naive 75 74
Ethnicity, %
Caucasian/white 82 86
African American/black 14 11
Asian/Paciﬁc Islander 0 1
Latin American/Hispanic 3 1
Arabic 0 0
Native American 1 0
Other 0 1
E.M. Roth et al.
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Supplemental Table II. Characteristics of patients from the United States and the European Union.*
Study Group United States (n) European Union (n)
Pen
Age o60 y 23 28
Age Z60 y 27 22
Syringe
Age o60 y 32 24
Age Z60 y 18 26
Pen
Male 25 23
Female 25 27
Syringe
Male 25 25
Female 25 25
Pen
Injection experienced 16 9
Injection-naive 34 41
Syringe
Injection experienced 8 18
Injection-naive 42 32
Pen
High CV risk 24 22
Diabetes 15 16
Statin-intolerant 10 11
FH 1 1
Syringe
High CV risk 31 27
Diabetes 13 19
Statin-intolerant 6 3
FH 0 1
CV ¼ cardiovascular; FH ¼ familial hypercholesterolemia.
*N ¼ 50 for each of the pen and syringe groups in both the United States and the European Union.
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